Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,845 USD | +3,83% | -3,38% | -54,42% |
Omzet 2022 | 22,3 mln. 20,85 mln. | Omzet 2023 | 7,19 mln. 6,73 mln. | Marktkapitalisatie | 25,42 mln. 23,76 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -62 mln. -57,97 mln. | Nettowinst (verlies) 2023 | -50 mln. -46,75 mln. | EV/omzet 2022 | 2,66 x |
Nettoschuld 2022 | 48,89 mln. 45,71 mln. | Nettoschuld 2023 | 33,81 mln. 31,61 mln. | EV/omzet 2023 | 8,23 x |
K/w-verhouding 2022 |
-0,12
x | K/w-verhouding 2023 |
-0,33
x | Werknemers | 113 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 49,08% |
Recentste transcriptie over T2 Biosystems, Inc.
1 dag | +3,83% | ||
1 week | -3,38% | ||
Lopende maand | -4,67% | ||
3 maanden | -32,23% | ||
6 maanden | -49,02% | ||
Lopend jaar | -54,42% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Sperzel
CEO | Chief Executive Officer | 60 | 08-01-20 |
John Sprague
DFI | Director of Finance/CFO | 65 | 30-01-18 |
Roger Smith
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Elsbree
BRD | Director/Board Member | 76 | 01-07-14 |
Seymour Liebman
BRD | Director/Board Member | 74 | 21-09-16 |
Robin Toft
BRD | Director/Board Member | 63 | 14-06-20 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 2,86 | +4,38% | 79 478 |
25-04-24 | 2,74 | -0,72% | 412 422 |
24-04-24 | 2,76 | +1,47% | 330 290 |
23-04-24 | 2,72 | -13,92% | 359 187 |
22-04-24 | 3,16 | +6,76% | 1 363 736 |
uitgestelde koers Nasdaq, 26 april 2024 om 19:12 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-54,42% | 24,09 mln. | |
+8,09% | 218 mld. | |
+7,15% | 182 mld. | |
+11,47% | 132 mld. | |
+26,78% | 108 mld. | |
+13,40% | 52,98 mld. | |
-0,62% | 47,59 mld. | |
-0,66% | 39,96 mld. | |
+11,37% | 39,22 mld. | |
+25,93% | 26,94 mld. |